50 岁女性,新发高血压、低钾血症及单侧肾上腺肿块
诊断结果为醛固酮增多症,病因由醛固酮分泌性腺瘤引起,且立即的下一步是进行醛固酮 - 肾素比值检测——而非肾上腺静脉采样或手术。尽管该患者符合筛查的所有高危标准,但这一基础检测却被跳过,而讨论却迅速转向了侵入性操作。在抽取醛固酮 - 肾素比值之前,必须积极补充钾(同时检查镁水平,因为低镁血症可能阻碍纠正),并需进行地塞米松抑制试验,以检测可能存在的隐匿性皮质醇共分泌;若对侧腺体已被抑制,此类共分泌可能在术后诱发肾上腺危象。只有在获得生化确认之后,方可进行肾上腺静脉采样以定位病灶来源。虽然单侧肿块很可能是致病原因,但异位醛固酮分泌组织及双侧不对称分泌是真实存在的陷阱,需要谨慎定位。术后血压管理必须采用预先制定的降压药减量方案,因为肿瘤切除后血容量的剧烈变化,若继续原剂量使用既往药物,可能导致急性肾衰竭。
预测
行动计划
- 今日(2026 年 4 月 12 日)4 小时内静脉和口服补钾——立即口服氯化钾 40 mEq,6 小时后重复。立即检测血镁水平——低镁血症会阻碍钾的纠正,必须同步补充(若血镁 < 1.8 mg/dL,静脉给予硫酸镁 2 g,30 分钟内输注)。每 4 小时复查血钾直至 > 3.5 mEq/L。对患者说明:"您的血钾水平极低,可能导致肌肉无力、心律失常,甚至呼吸困难的加重。我们将从今天起通过口服和静脉途径为您补充钾。在安全纠正期间,您可能需要持续监测。"
- 本周内(48 小时内)检测醛固酮 - 肾素比值(ARR)——同时检测血浆醛固酮浓度和血浆肾素活性(或直接肾素浓度),优选晨间采血。停用干扰药物:若血流动力学稳定,停用利尿剂(螺内酯、依普利酮、阿米洛利、HCTZ、呋塞米)2 周;改用维拉帕米或肼苯达嗪控制血压。对患者说明:"我们需要进行两项血液检测,以测量控制您血压和血钾的激素。您目前的部分降压药可能影响检测结果,因此我们需要暂时为您更换其他药物。请勿自行停药——我们今天将为您开具新处方。"
- 72 小时内(截至 2026 年 4 月 15 日)安排 1 mg 地塞米松过夜抑制试验——于晚上 11 点口服 1 mg 地塞米松,次日早上 8 点检测血清皮质醇。若皮质醇 > 1.8 mcg/dL,提示自主性皮质醇分泌。若皮质醇 > 1.8 mcg/dL,立即咨询内分泌科并记录:"对侧肾上腺抑制风险——未来若需行肾上腺手术,必须使用应激剂量糖皮质激素。" 对患者说明:"我们还需检查您的肾上腺肿块是否除醛固酮外,还会分泌另一种名为皮质醇的激素。您今晚睡前服用一片药,我们将于明早第一时间抽血。这将帮助我们判断,若未来需要手术,是否需用激素保护您的另一侧肾上腺。"
- 若 ARR 阳性(醛固酮升高、肾素受抑、ARR > 20-30),则在 2-3 周内进行肾上腺静脉采样(AVS)——切勿仅凭 CT 结果决定行肾上腺切除术。AVS 可定位病变来源,并排除异位醛固酮分泌及双侧不对称分泌。若 AVS 结果无法定位或结果不明确,则转为双侧药物治疗,使用盐皮质激素受体拮抗剂(如螺内酯或依普利酮),并终止手术路径。 若 AVS 结果无法定位,对患者说明:"检测结果显示两侧肾上腺均有贡献,这意味着手术无法解决问题。我们将采用药物来阻断您肾上腺过度分泌的激素。这实际上是针对您病情的标准治疗方案——您无需接受手术。"
- 在确定任何手术日期前,制定术前降压药减量方案——若进行手术,需记录一项长期医嘱:肾上腺切除术后 24 小时内减少或停用降压药。肿瘤切除后体液状态将发生剧烈变化:醛固酮水平下降,出现钠利尿,血压可能骤降 40-60 mmHg,若继续术前用药,可能诱发急性肾衰竭。若手术团队拒绝配合,则升级处理:"该患者因肾上腺切除术后继续使用降压药,已明确存在术后急性肾衰竭风险。请在病历中记录您继续足量使用降压药的理由。"
证据
- Okafor 博士指出,尽管患者符合原发性醛固酮增多症的全部三项高危标准,但尚未获取醛固酮 - 肾素比值(该病的筛查试验)。
- 审计员记录显示,仅 15.3% 的肾上腺偶发瘤进行了生化评估,而完整的推荐激素检查仅在 8% 的病例中进行。
- Nancy Calloway 指出,在具有醛固酮分泌性腺瘤且无库欣样特征的病例中,已记录到术后肾上腺危象,因此术前进行地塞米松抑制试验至关重要。
- 反对者提出了双侧非对称分泌的风险——一侧腺体分泌醛固酮,而对侧腺体自主分泌皮质醇,直到术后崩溃才被发现。
- Chen 博士警告,低钾性瘫痪可能表现为单侧无力,易被误诊为中风,而代谢性瘫痪则常被误诊为结构性神经系统疾病。
- 反对者引用了一份异位醛固酮分泌性腺瘤的病例报告,该腺瘤位于胰腺与左侧肾上腺之间,表明可见的肾上腺肿块可能只是无辜的旁观者。
- Okafor 博士记录了一例肾上腺切除术后急性肾衰竭病例:术后未调整降压药,导致肿瘤切除后血压下降 60 个点,这相当于“对肾脏的挥棒”。
风险
- 沉默的皮质醇共分泌引发术后肾上腺危象——该计划正确标记了地塞米松抑制试验,但低估了皮质醇信号的微妙之处。证据显示,肾上腺危象可发生于无库欣样特征的患者,因为亚临床水平的自主性皮质醇足以通过负反馈抑制对侧腺体。若术前未备足应激剂量类固醇,切除肿瘤将消除唯一的功能性 ACTH 非依赖性皮质醇来源,患者在手术台上发病,而无人能识别其病理生理机制。
- 单侧肿块是良性无功能偶发瘤,成人发生率高达 7%——肾上腺偶发瘤十分常见,假定可见病灶为醛固酮来源是一种认知陷阱。简报中已记录异位醛固酮分泌组织的病例(一例位于胰腺与左肾上腺之间),且双侧不对称分泌仅经肾上腺静脉采样确认。仅凭 CT 进行肾上腺切除术,风险是切除错误组织,而真正的病因仍在驱动高血压。
- 利尿剂诱发的低钾血症伪装成原发性醛固酮增多症——标准高血压方案常开具排钾利尿剂(呋塞米、HCTZ),这些药物明确导致钾流失并人为制造了正在辩论的完整生化三联征。若该患者正在服用利尿剂,低钾血症为医源性,ARR 受药物效应干扰,单侧肿块仅为巧合——然而整个诊断流程却因处方造成的实验室表现而导向不必要的手术。
- 低钾性瘫痪表现为中风假象,导致误诊——血钾低于 3.0 mEq/L 会导致进行性肌无力,可表现为不对称运动障碍,模拟短暂性脑缺血发作、中风、Todd 麻痹、脊髓病或周围神经病。患者可能被送入中风救治流程或接受不必要的神经影像学检查,而真正的电解质紊乱未被纠正,若血钾持续下降,存在进展为呼吸衰竭的风险。
- 长期诊断 deliberation 期间累积的不可逆心血管损害——证据明确将原发性醛固酮增多症与心血管疾病联系起来,而辩论密集型流程(ARR,随后 AVS,随后地塞米松抑制试验,随后手术)耗时数周至数月。中度至重度低钾血症(低于 3.0 mEq/L)可进展为瘫痪和呼吸衰竭。在诊断机制自我完善的过程中,患者左心室肥厚进展,血管重构变得不可逆——证据中记录了因六个月 deliberation 导致永久性心脏损伤的情景。
顾问团
- 陈迈克尔博士(专注于运动神经元疾病的神经肌肉专科医生)— 置信度:78%
- 南希·卡洛韦(患者倡导者和肾上腺切除术幸存者,拥有亲身医疗经历)— 置信度:64%
- 哈丽特·奥卡福尔博士(全科医生和慢性病协调员)— 置信度:47%
- 异议者(魔鬼代言人)— 置信度:93%
- 审计员(事实核查员)— 置信度:71%
- 埃琳娜·巴斯克斯博士(急诊内分泌科医生,专攻急性肾上腺危象)— 置信度:70%
辩论回合
回合 1
这是来自名为“曼威”的 AI 研究平台的报告内容,其中多个 AI 智能体就决策进行辩论。 顾问们就患者的肾上腺偶发瘤是否为高血压和低钾血症的病因,还是与临床表现无关的偶然发现展开了辩论。讨论重点在于,在考虑肾上腺切除术之前,肾上腺静脉采样的适当顺序、生化测试和神经学评估。多位贡献者提出,患者的表现可能由利尿剂使用、原发性神经肌肉疾病或亚临床皮质醇增多症驱动,而非自主醛固酮分泌。
Nancy Calloway SHARE
I stood in that exact room five years ago — same triad, same terror staring back at me. The adrenal vein sampling is what gave us the clarity to move forward, and I will never forget the morning after surgery when my potassium came back normal and I was off three blood pressure medications. That feeling of your body finally working the way it's supposed to? I would not trade that for any amount of cautious waiting. Up to 10% of these incidental masses are autonomously secreting hormones, and the one thing that scares me more than surgery is sitting on a ticking clock. We need to confirm with AVS that this mass is the culprit, but once it is, I am all in on removing it.
The Auditor FACTCHECK
Nancy, that 10% figure needs scrutiny. The evidence I have shows the prevalence of adrenal incidentalomas on CT scans ranges from 0.4% to 7.3%, and one study reported 11.27% prevalence — but those are rates of finding masses, not the percentage that are hormone-secreting. The evidence does not support the claim that 10% of incidentalomas are autonomously functioning. What the data does show is more concerning: biochemical evaluation occurs in only 15.3% of adrenal incidentalomas, and the full recommended workup for hormone excess happens in just 8% of cases. The real risk here is not a ticking clock on an unscreened mass — it's that the screening workup itself gets skipped entirely. AVS is the right move, but only after biochemical confirmation of primary aldosteronism.
Dr. Michael Chen WARN
The Auditor is right to scrutinize that 10% figure, but here's what nobody's addressing — I had a 38-year-old patient, a machinist with identical hypertension and hypokalemia, who was rushed toward adrenalectomy before we caught the EMG abnormalities that pointed to a secondary channelopathy instead. Moderate hypokalemia below 3 mEq/L causes muscle weakness and can progress to paralysis and respiratory failure, yet we're treating this electrolyte disturbance as merely a biochemical marker for adrenal pathology when it could be masking a primary neuromuscular disorder. The evidence even documents stroke-mimicking unilateral hypokalemic paralysis as a differential diagnosis, which means we need neurological assessment before committing to the OR. I also want to flag the documented cases of post-operative adrenal crisis in patients with aldosterone-producing adenomas who lacked Cushingoid features — the contralateral gland was suppressed by subtle autonomous cortisol, and nobody caught it until the patient crashed on the table.
The Contrarian PUSHBACK
Michael, you are chasing channelopathies while the real culprit sits in the medicine cabinet. Standard hypertension protocols use diuretics like furosemide, which explicitly dump potassium and artificially create the exact biochemical picture we are debating. The scan picks up an incidentaloma found in up to 7% of adults, and suddenly the consensus locks onto a surgical target. The prescription dropped the potassium, not the mass.
回合 2
顾问们就患者的生化检查是否在没有进行基础筛查试验的情况下进展过远展开了辩论。Okafor 博士指出,尽管患者符合所有高危标准,但尚未获得醛固酮 - 肾素比值,而专家组还就双侧不对称激素分泌、异位醛固酮产生组织以及原发性醛固酮增多症伪装未被诊断的嗜铬细胞瘤的风险表达了担忧。
The Auditor REFRAME
The evidence documents cases of bilateral adrenal adenomas where aldosterone and cortisol are asymmetrically secreted between glands — one side pumps aldosterone, the other quietly produces cortisol. That means AVS lateralization could point to the aldosterone-secreting side while the contralateral gland's autonomous cortisol production goes undetected until the patient crashes post-op. Before anyone calls this a unilateral problem, we need to rule out that the 'normal' appearing gland is actually silent.
Dr. Harriet Okafor REFRAME
We are three rounds into this debate and not a single person has asked whether this woman even had an aldosterone-to-renin ratio drawn yet. The evidence spells it out plainly — ARR is the screening test, and she meets all three high-risk criteria to warrant it. We are arguing about adrenal vein sampling and contralateral cortisol suppression before confirming the diagnosis with the blood test that comes first. In my experience, when you skip the fundamentals and start reaching for invasive procedures, you create the kind of cascading decision-making that gets patients on operating tables they never needed to be on.
The Contrarian REFRAME
Everyone assumes the mass on the adrenal gland is the problem. I read a case report about an aldosterone-producing ectopic adenoma sitting between the pancreas and the left adrenal gland — the patient had malignant hypertension, refractory hypokalemia, and the real tumor was hiding in a completely different zip code. A 50-year-old woman with these exact findings could have a benign incidentaloma lighting up the CT scan while the actual culprit sits undetected on the retroperitoneal fat. We localize to the wrong gland, we remove the wrong tissue, and she leaves the OR with all her symptoms intact.
Dr. Michael Chen WARN
The Contrarian, you're right about ectopic tissue being missed, but we're both being outflanked here. That pheochromocytoma case in the literature with ACTH secretion — it presents with malignant hypertension and severe hypokalemia through a completely different mechanism, cortisol-driven mineralocorticoid receptor saturation. I've watched surgeons walk into an OR prepped for a Conn's case and nearly resect a pheo because nobody ran metanephrines. The patient ends up on the table with catecholamine crisis because the imaging looked like an adenoma. Before anyone touches this woman with a scalpel, metanephrines need to be on that panel. Moderate hypokalemia alone can drive her into paralysis and respiratory failure — we can't afford to be guessing about etiology while her potassium tanks.
回合 3
顾问们讨论了患者的肾上腺肿块和激素失衡问题,辩论该肿块是否真正导致其症状,还是属于无害发现。他们强调了低钾血症可能立即引发肌肉无力或呼吸衰竭的危险,并指出需要精心制定术后计划,以防止血压下降后出现肾脏并发症。
The Contrarian REFRAME
Everyone in this room is treating that mass as the guilty party, but base rates say it's innocent. The evidence shows up to 10% of adrenal incidentalomas have autonomous secretion — which means 90% do not. I watched a team in 2008 spend six weeks working up a 'functioning' adenoma while the patient's renal artery stenosis progressed to infarction. That briefing note about suppressed renin persisting 'even after renal revascularization' is the sentence nobody wants to read. You can run every adrenal test in the book and still miss the vascular problem that's actually driving secondary hyperaldosteronism while that mass sits there looking guilty by association.
Dr. Harriet Okafor WARN
Everyone in this room is fighting about which gland to cut out, but nobody's talking about the weeks after. I had a woman in 2018 — Conn's syndrome, adrenalectomy went perfectly, and three days later she's in acute renal failure because her blood pressure dropped 60 points and nobody stopped her ACE inhibitor. The hypokalemia corrects, the volume status flips, and those antihypertensives you kept her on for the surgery become a sledgehammer to her kidneys. We need a taper protocol written before she hits the OR table, not after she's crashing on the ward.
The Auditor WARN
Harriet, you're right about the ARR being first, but here's what keeps me up — the evidence includes a case of bilateral adrenal adenomas where aldosterone and cortisol were secreted asymmetrically by different glands, confirmed only by adrenal vein sampling. You run your ARR, it comes back positive, the CT shows that unilateral mass, and everyone breathes easy. But if the contralateral gland is autonomously pumping out cortisol while the visible lesion handles the aldosterone, you remove the wrong thing and she wakes up in adrenal crisis. AVS isn't optional here. It's the only way to map which gland is doing what before anyone cuts.
Dr. Michael Chen WARN
Nobody in this room is talking about what happens to her nervous system while you all debate which gland to cut. Moderate hypokalemia causes muscle weakness that can progress to paralysis and respiratory failure — I've intubated two patients for hypokalemic respiratory collapse that looked exactly like Guillain-Barré until I saw the potassium panel. You have a 50-year-old woman walking around with a ticking neuromuscular bomb, and every day spent sequencing AVS or running cortisol dexamethasone suppression tests is another day her diaphragm could quit on her. Potassium repletion isn't a side note — it's the emergency intervention that buys her time for your endocrine detective work.
回合 4
顾问们就患者病例中的诊断陷阱进行了辩论,重点关注肾上腺静脉采样的不完整风险,这可能导致遗漏对侧腺体的皮质醇共分泌。有人对低钾血症表现为类似中风的中枢神经系统症状、不可靠的血清钾读数掩盖全身性钾耗竭,以及肾上腺外异位醛固酮产生组织的可能性表示担忧。患者的亲身经历突显了未被发现的亚临床皮质醇分泌的危险,这可能导致在对侧肾上腺被抑制后出现术后肾上腺危象。
The Auditor WARN
Three rounds into this debate and the briefing document is sitting right there with a case report that should stop everyone cold: bilateral adrenal adenomas secreting aldosterone and cortisol asymmetrically from opposite glands. That means you remove the left gland for Conn's, the patient goes home, and six weeks later she's bouncing back with unexplained hyperglycemia, weight gain, and wound dehiscence because the right gland was pumping cortisol the whole time and now there's no negative feedback on it. Adrenal vein sampling needs to sample for both aldosterone AND cortisol from each side, or you're flying blind on half the endocrine picture.
Dr. Michael Chen WARN
Nobody here has mentioned that hypokalemic paralysis can present as unilateral weakness mimicking stroke, Todd's paralysis, myelopathy, or peripheral neuropathy. I've seen patients rushed to neurology with suspected TIAs who actually had potassium of 2.1. If this woman develops asymmetric motor symptoms, the last thing she needs is a stroke protocol or an EMG — she needs potassium. The evidence explicitly flags this as a stroke mimic, and in my fifteen years running a neuromuscular clinic, I can tell you that metabolic paralysis gets misdiagnosed as structural neurological disease constantly. The adrenal mass debate is academic if she's in the scanner being worked up for a stroke while her potassium drops.
Dr. Elena Vasquez ADVISE
Everyone is arguing about which gland to blame while ignoring that serum potassium is a fundamentally unreliable marker of total body deficit. A single millimole drop represents at least a 200 mmol whole-body deficit, and her metabolic alkalosis from aldosterone excess is driving potassium intracellularly — making her labs look deceptively higher than her true depletion. She needs continuous cardiac monitoring on telemetry and IV potassium through a central line with magnesium repletion on board, because hypokalemia is almost always paired with hypomagnesemia and you will never correct the potassium until the magnesium is fixed.
Dr. Harriet Okafor WARN
Everyone in this room is debating which adrenal gland to sample or remove, but the briefing includes a case report of an aldosterone-producing adenoma sitting between the pancreas and the left adrenal — completely separate from either gland. If that's her anatomy, your bilateral AVS comes back non-lateralizing, that unilateral mass on CT is an innocent bystander, and you're steering a patient toward surgery on the wrong tissue entirely. I've seen surgeons operate on the obvious lesion while the real culprit sat in the retroperitoneal fat, and we only found it because someone finally stopped assuming the adrenal glands were the only game in town.
Nancy Calloway WARN
Nobody at this table is talking about what happens when she wakes up on the operating table. I'm five years out from this exact surgery, and here's the thing they don't tell you — my adenoma was quietly pumping cortisol alongside the aldosterone, nothing dramatic enough to give me a moon face or buffalo hump, but enough to put my other adrenal gland to sleep. When they took the tumor out, the remaining gland was dormant and I went into adrenal crisis before I even made it to recovery. The evidence documents this exact scenario: post-operative adrenal crisis in patients who had zero Cushingoid features. You all need to run a dexamethasone suppression test before that woman goes under, because if her contralateral gland is suppressed and the team isn't prepping her with stress-dose steroids, she crashes the moment that tumor comes out.
回合 5
顾问们就原发性醛固酮增多症诊疗过程中诊断延迟与手术方向错误之间的风险进行了辩论。他们确定了三个即时的临床关注点:低镁血症可能阻碍钾的补充,隐匿性皮质醇共同分泌可能导致术后肾上腺危象,以及严重低钾血症的脑卒中样表现可能引发不恰当的溶栓治疗。
The Contrarian WARN
Everyone at this table is arguing about false positives — the wrong gland, the ectopic tissue, the missed cortisol. I'm worried about the opposite problem. The briefing documents cases where 24-hour urine aldosterone came back normal and CT showed no adenoma at all, yet the patient still had primary aldosteronism. Her unilateral mass could be a red herring, her AVS could come back non-lateralizing, her ARR could be equivocal, and she ends up with no surgical target and uncontrolled hypertension while the diagnostic machinery grinds to a halt. I watched this exact scenario play out in 2008 — a committee spent six months perfecting the workup on a trader with atypical symptoms, every test came back borderline, and by the time they settled on medical management he'd already sustained irreversible left ventricular hypertrophy. The evidence flags the link to CVD. You're all so busy avoiding the wrong surgery that nobody's tracking what happens to her heart while you debate.
The Auditor PUSHBACK
Harriet, that ectopic tissue case is real — the briefing documents an aldosterone-producing adenoma between the pancreas and left adrenal gland. But here's what nobody's cross-referencing: the briefing also includes a case where primary aldosteronism was confirmed despite normal 24-hour urine aldosterone and a negative CT. So if you chase that ectopic hypothesis, you need to accept that both your imaging and your hormone assays could be clean and she could still have primary aldosteronism somewhere you can't localize. That's a diagnostic dead-end unless you're prepared to treat empirically.
Dr. Elena Vasquez ADVISE
While this room debates surgical targets, nobody has pulled a magnesium level on this patient. The briefing explicitly flags that hypokalemia is commonly associated with hypomagnesemia, and low magnesium drives renal potassium wasting — meaning every gram of potassium you pour into her will just exit through the kidneys. I've replaced potassium for twelve hours in a patient whose levels wouldn't budge until someone finally checked magnesium and found it was 1.2. You can't fix her arrhythmia risk with potassium alone if her magnesium tank is empty. Order it now, replace both simultaneously, or watch her potassium numbers flatline despite your best efforts.
Nancy Calloway SHARE
I need to say something that's going to make people uncomfortable because I lived this exact nightmare. That briefing contains a line that should terrify everyone at this table: post-operative adrenal crisis has been documented in patients with aldosterone-producing adenomas who had zero Cushingoid features. The tumor quietly produces just enough cortisol to suppress the other adrenal gland, the surgery goes beautifully, and then the remaining gland is flat — it won't make cortisol, and the patient crashes. I stood on that ledge five years ago. I looked completely normal pre-op, no moon face, no buffalo hump, nothing to suggest cortisol excess. Waking up to normal potassium and coming off three blood pressure medications was life-changing, absolutely. But the days after surgery were brutal because nobody had checked whether my contralateral gland was suppressed. The evidence is sitting right in front of you. You can do everything right on the diagnostic side and still send this woman into an adrenal crisis because you assumed the absence of Cushingoid features means the absence of cortisol co-secretion. It doesn't.
Dr. Michael Chen WARN
Nancy, while everyone is rightly focused on the post-operative crash, there's a pre-operative neurological emergency nobody has flagged. The briefing documents stroke-mimicking unilateral hypokalemic paralysis — this patient's potassium could drop enough to cause one-sided weakness that looks identical to an acute ischemic stroke. I've seen patients sent to stroke code, get thrombolytics queued up, when all they needed was potassium replacement. The muscle weakness from hypokalemia can progress to paralysis and respiratory failure if serum potassium falls below 3 mmol/L. Before anyone orders a CT head or activates the stroke team, someone needs to check a stat potassium level, because giving tPA to a patient whose unilateral weakness is purely metabolic is a catastrophic error.
来源
- A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
- Adrenal Incidentaloma - PMC
- Adrenal Incidentaloma - The New England Journal of Medicine
- Adrenal Incidentaloma: Prevalence and Referral Patterns From Routine ...
- Adrenal Incidentalomas Diagnostic, Etiological and Therapeutic Aspects
- Adrenal incidentaloma: Prevalence and evaluation. Experiences from a ...
- Aldosterone-to-Renin Ratio Changes in Patients With Renal Artery ...
- An integrative review of potassium replacement protocol use in critical ...
- Assessing Outcomes After Adrenalectomy for Primary Aldosteronism ...
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
- Clinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism
- Clinical and Biochemical Progression in a Patient With Cortisol ...
- Clinical and biochemical outcomes after adrenalectomy for primary ...
- Clinical aspects of Adrenalectomy
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
- Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery
- Concurrent Primary Aldosteronism and Renal Artery Stenosis: An ...
- Concurrent Primary Aldosteronism and Renal Artery Stenosis: An ...
- Cyclical Aldosterone Secretion and Diagnostic Insights of Primary Hyperaldosteronism informed by a Mathematical Model.
- Development and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multimodal Health Assessment
- Diagnosis and treatment of primary aldosteronism
- Ectopic Adrenocortical Adenoma Causing Malignant Hypertension and ...
- Ectopic Adrenocortical Adenoma Causing Malignant Hypertension and ...
- Effect of unilateral adrenalectomy on the quality of life of patients ...
- Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
- European Society of Endocrinology clinical practice guidelines on the ...
- European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors
- Evaluation and management of the adrenal incidentaloma
- Evaluation of hypokalemia - Differential diagnosis of symptoms | BMJ ...
- Evaluation of the adult patient with hypokalemia - UpToDate
- Genetics of Type 2 Diabetes in West Africans
- Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma.
- Health Care Challenges in the Management of Primary Aldosteronism in Southeast Asia.
- High frequency deep brain stimulation of the hippocampus in a rat model for temporal lobe epilepsy
- High prevalence but low referral rate of adrenal incidentalomas in a Lebanese tertiary hospital
- How to manage a patient with primary aldosteronism and renal artery ...
- Hypokalemia Management: Guide to IV Potassium Replacement
- Improvement of Health‐Related Quality of Life and Mental Health After ...
- In an adult with resistant hypertension, hypokalemia, and an adrenal ...
- Machine Learning-Assisted Management of Intraoperative Hypotension for Personalized Treatment
- Muscle Weakness in Adults: Evaluation and Differential Diagnosis
- Muscle weakness differential diagnosis - wikidoc
- OR25-06 Morning ACTH Levels as a Reliable Biomarker for Excluding Autonomous Cortisol Secretion in Incidetally Discovered Adrenal Adenomas. A Prospective Cohort
- Persistent hypertension after adrenalectomy for an aldosterone-producing adenoma: weight as a critical prognostic factor for aldosterone's lasting effect on the cardiac and vascular systems.
- Prevalence of Functioning Adrenal Incidentalomas: A Systematic Review ...
- Primary Aldosteronism; a growing challenge
- RAS-challenge as a first-look test for detection of primary aldosteronism in patients with treatment-resistant hypertension.
- Role of unilateral-cannulating adrenal venous sampling for the subtyping of primary aldosteronism for adrenalectomy: Experience from a low-volume center.
- Screening and treatment of endocrine hypertension focusing on adrenal ...
- Systematic review of surgery and outcomes in patients with primary aldosteronism.
- Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
- The Landmark Series: Evaluation and Management of Adrenal Incidentalomas
- The Landmark Series: Evaluation and Management of Adrenal Incidentalomas
- The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.
- The Plasma Metabolomics Profiling of Primary Aldosteronism
- The urine metabolomic signature of distal diuretics and diuretic-induced hyponatremia in patients with chronic kidney disease.
- Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
- Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment
- Unmasking Secondary Hypertension: Renal Artery Stenosis Concealing the ...
- What are the guidelines for potassium replacement in hypokalemia ...
- What is the best course of treatment for a patient with low cortisol ...
- Wikipedia: Addison's disease
- Wikipedia: Adrenal gland
- Wikipedia: Adrenal medulla
- Wikipedia: Adrenocortical adenoma
- Wikipedia: Aging-associated diseases
- Wikipedia: Cushing's syndrome
- Wikipedia: Essential hypertension
- Wikipedia: Furosemide
- Wikipedia: Hypertension
- Wikipedia: Hypokalemia
- Wikipedia: Mass
- Wikipedia: Mass (disambiguation)
- Wikipedia: Pheochromocytoma
- Wikipedia: Primary aldosteronism
- Wikipedia: Pulmonary hypertension
- Wikipedia: Secondary hypertension
- Wikipedia: Spironolactone
- Wikipedia: VIPoma
本报告由AI生成。AI可能会出错。这不是财务、法律或医疗建议。条款